FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and is intended to treat or prevent mastitis in a mammal other than a human. Pharmaceutical composition comprising a mixture of phosphomycin and at least one antimicrobial agent selected from enrofloxacin, cefazolin, amoxicillin and pyrlymycin is used.
EFFECT: group of inventions can prevent, in particular, mastitis in cows, and also expand the arsenal of therapeutic agents.
10 cl, 6 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | 2014 |
|
RU2662300C2 |
| PREPARATION FOR TREATING MASTITIS IN COWS IN LACTATION PERIOD | 2019 |
|
RU2698820C1 |
| ENROFLOXACIN BASED TREATMENT OF MASTITIS | 2005 |
|
RU2413514C2 |
| COMBINATIONS OF LYSOBACTIN AND AMINOGLYCOSIDES AGAINST DISEASES CAUSED BY GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA IN NON-HUMAN ANIMALS | 2018 |
|
RU2760008C2 |
| LYSOBACTIN FOR USE IN TREATMENT OF BOVINE MASTITIS | 2016 |
|
RU2741764C2 |
| METHOD FOR INHIBITING THE GROWTH OF BACTERIAL MICROFLORA IN COWS WITH SUBCLINICAL MASTITIS | 2022 |
|
RU2784728C1 |
| METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | 2014 |
|
RU2675360C2 |
| METHOD FOR THE TREATMENT OF PURULENT-CATARRHAL MASTITIS IN COWS | 2021 |
|
RU2768607C1 |
| POLYMER COMPOSITES OBTAINED BY SOL-GEL METHOD, AND THEIR APPLICATION | 2016 |
|
RU2761212C2 |
| DISPERSIBLE PHARMACEUTICAL COMPOSITIONS | 2003 |
|
RU2311201C2 |
